The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://heathfpgy753978.wikibriefing.com/3953850/glp_3_retatrutide_a_comparative_analysis